Core Viewpoint - The increasing prevalence of myopia in China is driving a significant rise in the demand for myopia surgery, particularly among the youth, with a notable peak in surgeries during the summer months following the national college entrance examination [1][13]. Group 1: Market Trends - The myopia surgery market is experiencing robust growth, with a reported 1.5 surgeries per 1,000 people in China, and the average age of patients is around 24.7 years, predominantly under 20 years old [13][15]. - The market for myopia treatment has evolved beyond traditional eyewear, with myopia surgery becoming a prominent option among consumers [7][16]. - The myopia surgery market is characterized by a trend towards "quality consumption," with common procedures including corneal laser surgery and implantable contact lenses, priced between 15,000 to 30,000 yuan [15][16]. Group 2: Industry Dynamics - The demand for myopia surgery has attracted significant investment, leading to a proliferation of eye care institutions, including both chain brands and independent clinics [17][20]. - Aier Eye Hospital, a leading private eye care chain, has expanded its network from 71 to 974 facilities over nine years, highlighting the rapid growth in the sector [19]. - Other emerging players, such as Huaxia Eye Hospital and Puri Eye Hospital, are also expanding through financing and mergers, with Huaxia's assets increasing from 953 million yuan to 3.872 billion yuan from 2021 to 2024 [19]. Group 3: Service Diversification - Eye care institutions are diversifying their services to include comprehensive eye health management, from prevention to treatment and rehabilitation, thus providing consumers with more choices [22]. - Traditional eyewear retailers are also entering the myopia treatment market, leveraging their existing sales channels to offer myopia prevention and vision correction services [20]. Group 4: Challenges and Regulatory Issues - Despite the growth, the industry faces challenges, including the prevalence of misleading marketing practices and the sale of unapproved products, which can mislead consumers about the safety and effectiveness of myopia treatments [25][27][28]. - Regulatory bodies are increasingly focusing on combating false advertising in the myopia treatment sector, particularly concerning claims of "curing" myopia [28].